Laser-assisted subepithelial keratomileusis with mitomycin C for myopic astigmatism ≥2.00 diopters using a Zeiss MEL 80 Excimer

Standard

Laser-assisted subepithelial keratomileusis with mitomycin C for myopic astigmatism ≥2.00 diopters using a Zeiss MEL 80 Excimer. / Frings, A; Vidic, B; El-Shabrawi, Y; Ardjomand, N.

In: INT OPHTHALMOL, Vol. 34, No. 2, 01.04.2014, p. 225-33.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

APA

Vancouver

Bibtex

@article{439936b95fee47cda17b80ed0ec053c1,
title = "Laser-assisted subepithelial keratomileusis with mitomycin C for myopic astigmatism ≥2.00 diopters using a Zeiss MEL 80 Excimer",
abstract = "To examine the refractive and visual outcome of laser-assisted subepithelial keratomileusis (LASEK) with mitomycin C(MMC) in eyes with myopic astigmatism ≥2.00 diopters (D). This study comprised 82 eyes of 82 consecutive patients (37 male, 45 female; mean age at surgery 34.7 ± 9.0 years) with preoperative topographic astigmatism ≥2.00 D and mean preoperative spherical equivalent (SE) -4.50 ± 1.13 D. To assess whether the refractive results differed with the amount of corrected sphere, the data were separated by preoperative SE thereby defining two groups with SE < -5.00 D (-2.00 to -4.75 D) and ≥-5.00 D (-5.00 to -7.75 D). Mean manifest refraction spherical equivalent (MRSE) of -0.39 ± 0.52 D was obtained at the 6-months (5.4 ± 1.6 months) follow-up. The results were within ±1.00 D of the attempted correction in 89 % of patients. The mean postoperative corrected distant visual acuity was -0.02 ± 0.065 logMAR (range -0.10 to 0.15 logMAR). Sixty-seven (81.7 %) of all eyes did not change lines in safety. There was no statistically significant difference (P = 0.262) in safety between the SE groups. Mean efficacy was 0.89 ± 0.27. There was a statistically significant difference in efficacy (P = 0.024) between the preoperative SE groups. Larger ablation zones were associated with better visual outcome, confirmed by safety, efficacy and predictability. The data reported here demonstrated that LASEK using a Zeiss MEL 80 excimer laser with an additional application of MMC is a safe and efficient technique with predictable results for the correction of eyes with myopic astigmatism ≥2.00 D.",
author = "A Frings and B Vidic and Y El-Shabrawi and N Ardjomand",
year = "2014",
month = apr,
day = "1",
doi = "10.1007/s10792-013-9819-2",
language = "English",
volume = "34",
pages = "225--33",
journal = "INT OPHTHALMOL",
issn = "0165-5701",
publisher = "Springer Netherlands",
number = "2",

}

RIS

TY - JOUR

T1 - Laser-assisted subepithelial keratomileusis with mitomycin C for myopic astigmatism ≥2.00 diopters using a Zeiss MEL 80 Excimer

AU - Frings, A

AU - Vidic, B

AU - El-Shabrawi, Y

AU - Ardjomand, N

PY - 2014/4/1

Y1 - 2014/4/1

N2 - To examine the refractive and visual outcome of laser-assisted subepithelial keratomileusis (LASEK) with mitomycin C(MMC) in eyes with myopic astigmatism ≥2.00 diopters (D). This study comprised 82 eyes of 82 consecutive patients (37 male, 45 female; mean age at surgery 34.7 ± 9.0 years) with preoperative topographic astigmatism ≥2.00 D and mean preoperative spherical equivalent (SE) -4.50 ± 1.13 D. To assess whether the refractive results differed with the amount of corrected sphere, the data were separated by preoperative SE thereby defining two groups with SE < -5.00 D (-2.00 to -4.75 D) and ≥-5.00 D (-5.00 to -7.75 D). Mean manifest refraction spherical equivalent (MRSE) of -0.39 ± 0.52 D was obtained at the 6-months (5.4 ± 1.6 months) follow-up. The results were within ±1.00 D of the attempted correction in 89 % of patients. The mean postoperative corrected distant visual acuity was -0.02 ± 0.065 logMAR (range -0.10 to 0.15 logMAR). Sixty-seven (81.7 %) of all eyes did not change lines in safety. There was no statistically significant difference (P = 0.262) in safety between the SE groups. Mean efficacy was 0.89 ± 0.27. There was a statistically significant difference in efficacy (P = 0.024) between the preoperative SE groups. Larger ablation zones were associated with better visual outcome, confirmed by safety, efficacy and predictability. The data reported here demonstrated that LASEK using a Zeiss MEL 80 excimer laser with an additional application of MMC is a safe and efficient technique with predictable results for the correction of eyes with myopic astigmatism ≥2.00 D.

AB - To examine the refractive and visual outcome of laser-assisted subepithelial keratomileusis (LASEK) with mitomycin C(MMC) in eyes with myopic astigmatism ≥2.00 diopters (D). This study comprised 82 eyes of 82 consecutive patients (37 male, 45 female; mean age at surgery 34.7 ± 9.0 years) with preoperative topographic astigmatism ≥2.00 D and mean preoperative spherical equivalent (SE) -4.50 ± 1.13 D. To assess whether the refractive results differed with the amount of corrected sphere, the data were separated by preoperative SE thereby defining two groups with SE < -5.00 D (-2.00 to -4.75 D) and ≥-5.00 D (-5.00 to -7.75 D). Mean manifest refraction spherical equivalent (MRSE) of -0.39 ± 0.52 D was obtained at the 6-months (5.4 ± 1.6 months) follow-up. The results were within ±1.00 D of the attempted correction in 89 % of patients. The mean postoperative corrected distant visual acuity was -0.02 ± 0.065 logMAR (range -0.10 to 0.15 logMAR). Sixty-seven (81.7 %) of all eyes did not change lines in safety. There was no statistically significant difference (P = 0.262) in safety between the SE groups. Mean efficacy was 0.89 ± 0.27. There was a statistically significant difference in efficacy (P = 0.024) between the preoperative SE groups. Larger ablation zones were associated with better visual outcome, confirmed by safety, efficacy and predictability. The data reported here demonstrated that LASEK using a Zeiss MEL 80 excimer laser with an additional application of MMC is a safe and efficient technique with predictable results for the correction of eyes with myopic astigmatism ≥2.00 D.

U2 - 10.1007/s10792-013-9819-2

DO - 10.1007/s10792-013-9819-2

M3 - SCORING: Journal article

C2 - 23813344

VL - 34

SP - 225

EP - 233

JO - INT OPHTHALMOL

JF - INT OPHTHALMOL

SN - 0165-5701

IS - 2

ER -